Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Entertainment
  • Real Estate
  • Business
  • Technology
  • Artificial Intelligence
  • Non-profit
ncarol.com

Sydney Brachytherapy Group is the first private non-melanoma skin cancer clinic in Sydney to offer OncoBeta's Rhenium-SCT
ncarol.com/10192926

Trending...
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand - 108
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position - 106
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
Dr Joseph Grace at Sydney Brachytherapy Group Rhenium-SCT Personalised Treatment On Temple OncoBeta GmbH
SYDNEY - ncarol.com -- OncoBeta® GmbH, a medical device company specialising in innovative epidermal radioisotope therapies, today announces the Sydney Brachytherapy Group is the first private clinic in NSW performing Rhenium-SCT® for patients with non-melanoma skin cancers (NMSCs).

Rhenium-SCT® is an advanced radionuclide therapy technology that offers a non-invasive, predominantly single-session treatment with improved cosmetic outcomes for patients suffering from Basal Cell and Squamous Cell Carcinomas (BCCs and SCCs). With the global incidence rates of NMSCs increasing, and more than 7.7 million cases of NMSC being recorded each year1,2, this technology offers patients a new treatment option.

Dr Joseph Gracé, Medical Director of Sydney Brachytherapy Group says, "NMSC is a significant health concern here in Australia (especially for those with Fitzpatrick Skin Types I–III), and we are excited to offer Rhenium-SCT® to our patients with NMSC. The non-invasive nature of this treatment, especially for tumours in hard to reach anatomical locations, is one of the main reasons for using Rhenium-SCT®."

Standard treatments for NMSCs typically require surgery, whereas Rhenium-SCT® uses a non-invasive paste containing ß-emitting particles which are applied directly to a lesion to target cancer cells.3

"The key difference to other therapies is that the Rhenium-SCT® is more precise, allowing the physician to administer treatment locally without damaging surrounding tissue. Patients with difficult anatomic localisations of a tumour, such as ear, nose or anywhere on the face,  and those with larger lesions problematic for plastic surgery may benefit from this non-invasive solution, which provides preferrable aesthetic outcomes." adds Dr Gracé.

Shannon D. Brown III, CEO and Managing Director at OncoBeta, says, "This is a significant milestone in the international availability of  Rhenium-SCT® for patients in Australia,  and yet another step in having Rhenium-SCT® offered  in the suite of treatments available to patients suffering with NMSCs."

Sydney Brachytherapy Group is now taking patient referrals from dermatology and skin cancer specialists – for more information please visit: www.sydneybrachytherapy.com or for information about OncoBeta and Rhenium-SCT please visit:  www.oncobeta.com

More on ncarol.com
  • Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Designed for Healthcare: How TOLI Is Rethinking Functional Flooring
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth

About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.2 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.6
The Rhenium-SCT® is a painless*, single session†, non-invasive therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.3-5 The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalised therapy that is only applied to the area needed to treat without affecting the healthy tissue. The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT in one single session.†5 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.5

About OncoBeta®
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: www.linkedin.com/company/oncobeta-gmbh/
Facebook: www.facebook.com/oncobeta/

More on ncarol.com
  • ICG Homes Breaks Ground on the Triangle's 2027 St. Jude Dream Home
  • KayeDinero Takes Viewers Above Asheville in "Autumn in the Blue Ridge" Aerial Visual
  • PinnacleQM launches new enterprise website to help Australian organisations deliver more with confidence
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine

Instagram: www.instagram.com/oncobeta_gmbh/

About The Sydney Brachytherapy Group
The Sydney Brachytherapy Group is a multispecialist, multidisciplinary service of healthcare provided at the interventional suites at the North Shore Medical Group. Medical Director, Dr. Joseph Gracé chairs the medical advisory committee of Registered specialist medical practitioners (Visiting Medical Officers or VMO's), who are accredited by that committee. The VMO specialists include Nuclear Physicians, Dermatologists, Plastic Surgeons, Skin Cancer Surgeons and Oncologists. Sydney Brachytherapy is also participating in research and development and contributes to the International OncoBeta Skin Cancer Registry.
Phone: 02 8061 4048
Email: webcontact@sydneybrachytherapy.com
Website: www.sydneybrachytherapy.com
Address: Suite 304, 156-158 Pacific Highway
ST LEONARDS NSW 2065 Australia.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain3,4
†
Complete tumour regression in 98.5% of lesions treated5

References
  1. Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.
  2. Ciążyńska M, et al. Sci Rep. 2021;11(1):4337.
  3. Cipriani C, et al. J Dermatolog Treat. 2020; Jul 22:1-7.
  4. Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745-749.
  5. Cipriani C, Sedda AF. Therapeutic Nuclear Medicine, editor Baum RP; New York: Springer, 2014.
  6. Cancer.net. Skin Cancer (Non-Melanoma): Risk Factors and Prevention. October 2020. https://www.cancer.net/cancer-types/skin-cancer-non-melanoma/risk-factors-and-prevention (accessed March 2022).


Contact
Jane Morey
***@moreymedia.com.au


Source: OncoBeta GmbH

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Nious Media Expands Gaming Coverage With 2026 Game & Geek Expo Special
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • The Dark Chocolate Nutcracker Marks 15 Years
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
  • After Nvidia's 14% Drop, Asheville Artist KayeDinero Releases "Nvidia"
  • LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
  • Kitchen Table Economics: An Invitation to Think Differently
  • Gabby Press Earns High Praise From BookLife For Book About the Dangers of Corporate AI
  • Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
  • CB Stuffer Announces Private Sale to Secure Future of Brand Growth
  • The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
  • Apex Wellness Architect Hosts Intimate Tea & Intentions Tea Bar Experience to Close Out the Year
_catLbl0 _catLbl1

Popular on ncarol.com

  • Nious Media Expands Independent Entertainment Network Through Gaming, Music and Digital Storytelling - 228
  • Kestrel Ridge Health Launches AI-Powered Ophthalmology Workforce Forecasting Platform - 222
  • North Carolina Author Carrie Sybert Celebrates Three Published Books - 197
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki - 140
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs - 132
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration - 126
  • Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers - 121
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA) - 119
  • New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight - 112
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma - 109

Similar on ncarol.com

  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute